B. Anson, J. Weaver, M. Ackerman, O. Akinsete, K. Henry et al., Blockade of HERG channels by HIV protease inhibitors, The Lancet, vol.365, issue.9460, pp.682-688, 2005.
DOI : 10.1016/S0140-6736(05)70936-3

S. Benoit, A. Mendelsohn, P. Nourjah, J. Staffa, and D. Graham, Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey, European Journal of Cardiovascular Prevention & Rehabilitation, vol.348, issue.Suppl. 1, pp.363-371, 2005.
DOI : 10.1097/01.hjr.0000173110.21851.a9

I. Rodriguez, M. Kilborn, X. Liu, J. Pezzullo, and R. Woosley, Drug-Induced QT Prolongation in Women During the Menstrual Cycle, JAMA, vol.285, issue.10, pp.1322-1328, 2001.
DOI : 10.1001/jama.285.10.1322

L. Vitelli, R. Crow, E. Shahar, R. Hutchinson, P. Rautaharju et al., Electrocardiographic Findings in a Healthy Biracial Population, ARIC) Study Investigators, pp.453-462, 1998.
DOI : 10.1016/S0002-9149(97)00937-5

K. Becker, I. Gorlach, T. Frieling, and D. Haussinger, Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients, AIDS, vol.11, issue.6, pp.751-758, 1997.
DOI : 10.1097/00002030-199706000-00008

C. Mittal, N. Wig, S. Mishra, and K. Deepak, Heart rate variability in human immunodeficiency virus-positive individuals, International Journal of Cardiology, vol.94, issue.1, pp.1-6, 2004.
DOI : 10.1016/j.ijcard.2003.02.002

E. Fliers, H. Sauerwein, J. Romijn, P. Reiss, M. Van-der-valk et al., HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy, The Lancet, vol.362, issue.9397, pp.1758-60, 2003.
DOI : 10.1016/S0140-6736(03)14858-1

J. Robbins, J. Nelson, P. Rautaharju, and J. Gottdiener, The association between the length of the QT interval and mortality in the cardiovascular health study, The American Journal of Medicine, vol.115, issue.9, pp.689-94, 2003.
DOI : 10.1016/j.amjmed.2003.07.014

R. Goldberg, J. Bengtson, Z. Chen, K. Anderson, E. Locati et al., Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham heart study experience), The American Journal of Cardiology, vol.67, issue.1, pp.55-63, 1991.
DOI : 10.1016/0002-9149(91)90099-7

J. Karjalainen, A. Reunanen, P. Ristola, and M. Viitasalo, QT interval as a cardiac risk factor in a middle aged population., Heart, vol.77, issue.6, pp.543-551, 1997.
DOI : 10.1136/hrt.77.6.543

R. Van-heeswijk, M. Bourbeau, I. Seguin, P. Giguere, G. Garber et al., Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.35, issue.4, pp.398-404, 2005.
DOI : 10.1016/j.clpt.2003.11.121

M. Boffito, P. Hoggard, W. Lindup, S. Bonora, A. Sinicco et al., Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval, Therapeutic Drug Monitoring, vol.26, issue.1, pp.35-44, 2004.
DOI : 10.1097/00007691-200402000-00008

D. Jonker, L. Kenna, D. Leishman, R. Wallis, P. Milligan et al., A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data, Clinical Pharmacology & Therapeutics, vol.77, issue.6, pp.572-82, 2005.
DOI : 10.1016/j.clpt.2005.02.004